Chien-Nan Lee

Chien-Nan Lee

Auto-generated profile, based on publicly available information

Chien-Nan Lee

Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2003 in Oncogene
Verified
Journal Article
Closed access
LWLin-Hung Wei
Lin-Hung Wei
MKMin-Liang Kuo
Min-Liang Kuo
CCChi-An Chen
Chi-An Chen
CCChia-Hung Chou
Chia-Hung Chou
KLKuo-Bau Lai
Kuo-Bau Lai
CHChang-Yao Hsieh
Chang-Yao Hsieh

7 April 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
HCHuey‐Ling Chen
Huey‐Ling Chen
CLChien‐Nan Lee
Chien‐Nan Lee
CCChin‐Hao Chang
Chin‐Hao Chang
YNYen‐Hsuan Ni
Yen‐Hsuan Ni
MSMing‐Kwang Shyu
Ming‐Kwang Shyu
TSTaiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study)
Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study)
The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother‐to‐infant hepatitis B virus (HBV) transmissions is not clearly understood. We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)– and hepatitis B e antigen–positive pregnant women with HBV DNA ≥7.5 log10 IU/mL. The mothers received no medication (control group, n = 56, HBV DNA 8.22 ± 0.39 log10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 ± 0.47 log10 IU/mL) from 30‐32 weeks of gestation until 1 month postpartum. Primary outcome was infant HBsAg at 6 months old. At delivery, the TDF group had lower maternal HBV DNA levels (4.29 ± 0.93 versus 8.10 ± 0.56 log10 IU/mL, P < 0.0001). Of the 121/123 newborns, the TDF group had lower rates of HBV DNA positivity at birth (6.15% versus 31.48%, P = 0.0003) and HBsAg positivity at 6 months old (1.54% versus 10.71%, P = 0.0481). Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434) and amniocentesis was associated with higher risk (odds ratio 6.82, P = 0.0220) of infant HBsAg positivity. The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times the upper limit of normal for ≥3 months (3.23% versus 14.29%, P = 0.0455), a lesser extent of postpartum elevations of ALT (P = 0.007), and a lower rate of ALT over five times the upper limit of normal (1.64% versus 14.29%, P = 0.0135) at 2 months postpartum. Maternal creatinine and creatinine kinase levels, rates of congenital anomaly, premature birth, and growth parameters in infants were comparable in both groups. At 12 months, one TDF‐group child newly developed HBsAg positivity, presumably due to postnatal infection and inefficient humoral responses to vaccines. Conclusions: Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and infant HBsAg positivity at 6 months and ameliorated maternal ALT elevations. (Hepatology 2015;62:375–386

27 January 2009 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
JSJ. C. Shih
J. C. Shih
JJJ. M. Palacios Jaraquemada
J. M. Palacios Jaraquemada
YSY. N. Su
Y. N. Su
MSM. K. Shyu
M. K. Shyu
CLC. H. Lin
C. H. Lin
CLC. N. Lee
C. N. Lee
Objective: To assess the role of three‐dimensional (3D) power Doppler in the antenatal diagnosis of placenta accreta and compare its diagnostic performance with gray‐scale and color Doppler ultrasonography.Methods: One hundred and seventy pregnant women with persistent placenta previa totalis (after 28 weeks' gestation) were prospectively enrolled into this study. Gray‐scale transabdominal ultrasound examination was performed to detect loss of the subendometrial echolucent zone and other abnormalities suggestive of placenta accreta. Color flow mapping was used to scan the whole placenta to detect any newly formed vessels at the serosa–bladder border or the presence of abnormal lacunae. Finally a targeted examination of angioarchitecture in the basal and lateral views of the placenta was carried out using 3D power Doppler. The ultrasound findings were analyzed with reference to the final diagnosis made during Cesarean delivery.Results: Placenta accreta and its variants (including increta and percreta) were confirmed in 39 patients at the time of Cesarean delivery. Based on receiver–operating characteristics analysis, ‘numerous coherent vessels’ visualized using 3D power Doppler in the basal view was the best single criterion for the diagnosis of placenta accreta, with a sensitivity of 97% and a specificity of 92%. If we considered the presence of at least one criterion to be diagnostic when using each ultrasound technique, then 3D power Doppler would have the best positive predictive value (76%), followed by gray‐scale (51%) and color Doppler (47%). The majority of patients with placenta accreta showed multiple characteristic features on ultrasound imaging. In contrast, those patients with a false‐positive diagnosis (i.e. the final diagnosis was placenta previa alone) tended to show isolated ultrasound markers of the condition.Conclusion: 3D power Doppler may be useful as a complementary technique for the antenatal diagnosis or exclusion of placenta accreta. Copyright © 2009 ISUOG. Published by John Wiley & Sons, Ltd.

7 February 2012 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
CLC‐N Lee
C‐N Lee
SLShin-Yu Lin
Shin-Yu Lin
CLC‐H Lin
C‐H Lin
JSJ‐C Shih
J‐C Shih
TLT‐H Lin
T‐H Lin
YSY‐N Su
Y‐N Su


25 February 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YSYi-Ning Su
Yi-Ning Su
CHChia-Cheng Hung
Chia-Cheng Hung
SLShin-Yu Lin
Shin-Yu Lin
FCFang-Yi Chen
Fang-Yi Chen
JCJimmy P S Chern
Jimmy P S Chern
CLChien-Nan Lee
Chien-Nan Lee
Spinal muscular atrophy (SMA) is the most common neuromuscular autosomal recessive disorder. The American College of Medical Genetics has recently recommended routine carrier screening for SMA because of the high carrier frequency (1 in 25–50) as well as the severity of that genetic disease. Large studies are needed to determine the feasibility, benefits, and costs of such a program. This is a prospective population-based cohort study of 107,611 pregnant women from 25 counties in Taiwan conducted during the period January 2005 to June 2009. A three-stage screening program was used: (1) pregnant women were tested for SMA heterozygosity; (2) if the mother was determined to be heterozygous for SMA (carrier status), the paternal partner was then tested; (3) if both partners were SMA carriers, prenatal diagnostic testing was performed. During the study period, a total of 2,262 SMA carriers with one copy of the SMN1 gene were identified among the 107,611 pregnant women that were screened. The carrier rate was approximately 1 in 48 (2.10%). The negative predictive value of DHPLC coupled with MLPA was 99.87%. The combined method could detect approximately 94% of carriers because most of the cases resulted from a common single deletion event. In addition, 2,038 spouses were determined to be SMA carriers. Among those individuals, 47 couples were determined to be at high risk for having offspring with SMA. Prenatal diagnostic testing was performed in 43 pregnant women (91.49%) and SMA was diagnosed in 12 (27.91%) fetuses. The prevalence of SMA in our population was 1 in 8,968. The main benefit of SMA carrier screening is to reduce the burden associated with giving birth to an affected child. In this study, we determined the carrier frequency and genetic risk and provided carrier couples with genetic services, knowledge, and genetic counseling.